This is an IP milestone for a pre-revenue clinical-stage biotech. The patent strengthens Clearmind's position in alcohol use disorder and binge behavior regulation but does not change the company's near-term cash position or clinical timeline. Monitor for any subsequent clinical trial updates or partnership announcements related to CMND-100.
Price Chart
Executive Summary
Clearmind Medicine announced it was granted a U.S. patent (No. 12,350,242) by the USPTO for its MEAI molecule covering compositions and methods to regulate binge behaviors including excessive drinking, eating, and gambling. The patent expands the company's IP portfolio to 32 granted patents globally.
Key Facts
- U.S. Patent No. 12,350,242 granted titled 'BINGE BEHAVIOR REGULATORS'
- Patent covers Clearmind's molecule MEAI (5-methoxy-2-aminoindane)
- Company now has 32 granted patents across 19 patent families
- Patent relates to regulating binge behaviors including excessive drinking, eating, and gambling
- Company is a clinical-stage biotech focused on non-hallucinogenic neuroplastogens
Financial Impact
No financial figures or revenue impact disclosed in the filing
Risk Factors
- Company is pre-revenue with no approved products
- Forward-looking statements about clinical programs and IP expansion are aspirational
- No assurance that pending patent applications will issue in advantageous form
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-069873 |
| Document: ea029525002ex99-1.htm | 0001213900-26-069873 |
| Document: 0001213900-26-069873-index-headers.html | 0001213900-26-069873 |
| Document: 0001213900-26-069873-index.html | 0001213900-26-069873 |
| Document: 0001213900-26-069873.txt | 0001213900-26-069873 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $5.97 (+0.80%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $5.97 (−8.20%) |
Oct 16, 2026 11d ago | 6-K | $6.00 | awaiting T+60 | — | $5.97 (+0.55%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $5.97 (−4.22%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.97 (+602.04%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.97 (+602.04%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.97 (−13.06%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.97 (+532.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers